Paola Bresciani

Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

Simona Soverini, Caterina De Benedittis, Kateřina Machová Poláková et al. · Blood · 2013 · 162 citations · Full text

Medicine, Molecular Biology, Molecular Medicine +14

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

Simona Soverini, Caterina De Benedittis, Cristina Papayannidis et al. · Cancer · 2013 · 143 citations · Full text

Medicine, Hematology, Oncology +16

Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD

Attilio Olivieri, Michele Cimminiello, Paolo Corradini et al. · Blood · 2013 · 99 citations

Medicine, Pharmacotherapy, Immunotherapy +4

Persistent Carriage and Infection by Multidrug-Resistant Escherichia coli ST405 Producing NDM-1 Carbapenemase: Report on the First Italian Cases

Marco Maria D’Andrea, Claudia Venturelli, Tommaso Giani et al. · Journal of Clinical Microbiology · 2011 · 62 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

BCR-ABL–specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors

Patrizia Comoli, Sabrina Basso, Giovanni Riva et al. · Blood · 2016 · 57 citations · Full text

Medicine, Oncology, Pharmacology +12